Vasodilation through levodopa for Parkinson's disease may require high left ventricular assist device flow by Uil, C.A. (Corstiaan) den et al.
Received: 18 December 2018 | Revised: 26 January 2019 | Accepted: 19 February 2019
DOI: 10.1111/jocs.14012
CA S E R E POR T
Vasodilation through levodopa for Parkinson's disease may
require high left ventricular assist device flow
Corstiaan A. den Uil MD, PhD1,2 | Edith C. H. Friesema PhD3 |
Alina A. Constantinescu MD, PhD1
1Department of Cardiology, Mechanical
Circulatory Support and Cardiac
Transplantation, University Medical Center,
Thoraxcenter, Erasmus University Medical
Center, Rotterdam, the Netherlands
2Department of Intensive Care Medicine,
University Medical Center, Thoraxcenter,
Erasmus University Medical Center,
Rotterdam, the Netherlands
3Department of Internal Medicine, University
Medical Center, Section of Pharmacology,
Vascular and Metabolic Diseases, Erasmus
University Medical Center, Rotterdam, the
Netherlands
Correspondence
Corstiaan A. den Uil, cardiologist‐intensivist,
Erasmus University Medical Center, Room
Rg‐626, Postbox 2040, NL‐3000 CA,
Rotterdam, the Netherlands.
Email: c.denuil@erasmusmc.nl
Abstract
We report implantation of a left ventricular assist device (LVAD) in a patient with
Parkinson's disease. Postoperative fluid overload together with insufficient LVAD
output in the setting of vasodilation through levodopa likely caused renal
hypoperfusion and acute kidney injury. A patient like ours, therefore, requires the
highest possible increase of HM3 RPM and LVAD flow early after surgery.
K E YWORD S
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A 52‐year‐old male was admitted with INTERMACS III nonis-
chemic advanced heart failure. He had stable Parkinson's disease
treated with oral levodopa/carbidopa (200/50 mg SR and
150/37.5 mg 5 t.d.). His left ventricle was severely dilated end‐
diastolic diameter (EDD 94 mm). Filling pressures were high
(central venous pressure [CVP] 17 mm Hg, pulmonary capillary
wedge pressure [PCWP] 41 mm Hg, transpulmonary gradient
7 mm Hg). Fick calculated cardiac output (CO) was 3.8 L/minute.
He underwent uncomplicated HeartMate 3 implantation. The
postoperative course was marked by fatigue, but he was
discharged to the ward on day 5. He then developed progressive
dyspnea and renal failure. Two weeks after surgery, he was
readmitted to the ICU with pulmonary edema and anuric KDIGO
stage 3 acute kidney injury (AKI). LVAD parameters were normal
(5200 RPM, flow 4.0 L/min, power 3.8, pulse index 3.5). The NT‐
pro‐BNP level was 7319 pmol/L. The patient was intubated. Right
heart catheterization revealed: CO 5.1 L/min/m2, systemic vas-
cular resistance (SVR) 722 dynes/sec/cm5, CVP 14 mm Hg, PCWP
23 mm Hg, and SvO2 0.61. Transoesophageal echocardiography
demonstrated a dilated LV, rightward bulging of the septum, and
frequent aortic valve opening. Rotations were increased to 6200
RPM to produce an LVAD flow of 5.5 L/min, CO 8.5 L/min, and
SvO2 0.72. This change in settings led to 1:2 aortic valve opening,
an immediate increase of diuresis, resolution of pulmonary
edema, and full recovery of renal function.
What caused his normal‐output “heart” failure? Blood cul-
tures were negative. We did not find endocrine pathology.
Interrogation of the device represented a normal function. Chest
computed tomography demonstrated normal positions of both
LVAD and vascular prosthesis. We hypothesized that levodopa
may exert systemic vasodilatory effects for which a higher output
could be necessary (Figure 1).1 To investigate this hypothesis,
catecholamine levels were measured according to the available
standard extraction and derivation procedure using high‐perfor-
mance liquid chromatography with fluorometric detection.2 After
informed consent, blood was collected via an intravenous line,
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every 4 hours, during 48 hours, after 15 minutes of patient rest.
No vasoactive drugs were administered. Although the method
that we used could not reliably separate levodopa and dopamine
levels, all measured “dopamine” levels were highly elevated
(median 635, range 183‐1080 pg/mL; normal < 60 pg/mL). One
month later, predischarge, the same results were obtained (457
[175‐1564] pg/mL). The patient's 6‐minute walk distance at
discharge was 362 m (normal: > 380 m).
CONCLUSION
This is the first report of implantation of an LVAD in a patient with
Parkinson's disease on levodopa. Postsynaptic DA1 receptor
stimulation by dopamine from incomplete DOPA decarboxylase
inhibition, although not definitely proven due to the indistinguish-
able assay that we used, produces splanchnic vasodilation. These
effects may be aggravated by central inhibition of the sympathetic
nervous system.3 Postoperative fluid overload together with
insufficient LVAD output in the setting of vasodilation likely
caused renal hypoperfusion and AKI. A patient like ours therefore
requires the highest possible increase of HM3 RPM and LVAD flow
early after surgery.
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